Invesco Ltd. Inhibrx, Inc. Transaction History

Invesco Ltd.

$453 Billion
Q1 2024

A detailed history of Invesco Ltd. transactions in Inhibrx, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 12,449 shares of INBX stock, worth $176,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,449

Previous 50,086 75.14%

Holding current value

$176,402

Previous $1.9 Million 77.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$32.76 - $39.56 $1.23 Million - $1.49 Million	-37,637 Reduced 75.14%	12,449 $435,000
Q4 2023 Feb 12, 2024	BUY	$14.5 - $38.0 $450,602 - $1.18 Million	31,076 Added 163.47%	50,086 $1.9 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $631,953 - $1.06 Million	-40,124 Reduced 67.85%	19,010 $348,000
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $752,345 - $1.23 Million	44,360 Added 300.26%	59,134 $1.54 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $11,475 - $16,881	622 Added 4.4%	14,774 $278,000

Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $5,145 - $8,499	-255 Reduced 1.77%	14,152 $348,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $33,929 - $72,458	2,930 Added 25.53%	14,407 $259,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $1,013 - $3,005	119 Added 1.05%	11,477 $130,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $812,267 - $1.76 Million	-40,838 Reduced 78.24%	11,358 $253,000
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $204,958 - $352,605	-7,662 Reduced 12.8%	52,196 $2.28 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $1.29 Million - $1.94 Million	51,357 Added 604.13%	59,858 $1.99 Million
Q2 2021 Aug 17, 2021	BUY	$14.69 - $27.52 $124,879 - $233,947	8,501 New	8,501 $234,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account